Endovascular surgery

2024

Global Peripheral Artery Disease Devices Market Size Reaches $7.3 Billion

In 2024, expenditures on the global market for devices for the treatment of peripheral artery diseases amounted to $7.3 billion. More than 40% of this amount fell on the North American region. Such data are provided in a study by Grand View Research, the results of which Zdrav.Expert reviewed at the end of July 2025.

Peripheral artery diseases (PDAs) are a group of pathologies that are characterized by peripheral arterial channel damage, resulting in oxygen and nutrient deficiencies in the relevant areas of the body. Most often, the disease occurs in the arteries of the lower extremities: in this case, patients complain of leg pain when walking or during exercise. The cause of BDBA is the formation of atherosclerotic plaques in the lumen of the peripheral arteries, accompanied by a violation of the main function of the vessels. Due to narrowing of the arteries, the muscles get less blood, which leads to pain or convulsions. At risk are smokers, patients with overweight and diabetes mellitus, people with unfavorable heredity and hypertension.

One of the main drivers of the market, the authors of the study name the growing prevalence of diabetes and smoking. Both risk factors directly contribute to the progression of atherosclerosis - the main pathological mechanism of the development of BIA. According to the World Health Organization (WHO), from 1990 to 2022, the number of people with diabetes increased from 200 million to 830 million people, that is, more than four times. The prevalence of this ailment in the adult population rose from 7% to 14%. WHO statistics also show that as of January 2024, there were 1.25 billion adult tobacco users in the world. More than 7 million people a year die from the use of tobacco products, including about 1.6 million non-smokers exposed to secondary smoke.

Technological advances that change treatment strategies and improve the effectiveness of therapy have a positive impact on the industry. Next-generation products such as drug-eluting cylinders, atherectomy systems, and bioresorbable stents help reduce complications and accelerate patient recovery. The development of the market is also facilitated by the aging of the population: in the elderly, there is an age-related increase in the stiffness of the arteries, which may be accompanied by the development of concomitant diseases.

The study authors segment the industry into endovascular and surgical devices. In 2024, the lion's share of revenue was provided by the first type of products - 65.9%. Anatomically, 44.7% of the costs were for the femoral-popliteal segment. From a geographical point of view, North America led with 43.5%: the dominance of the region is due to the prevalence of BDBA, developed health infrastructure and a high level of adoption of endovascular technologies. Globally, significant players are named:

• BD (Becton Dickinson);
• Bentley InnoMed;
• Scitech Medical;
• Abbott Laboratories;
• Boston Scientific;
• W. L. Gore & Associates;
• Medtronic;
• Cook;
• Terumo Corporation;
• iVascular;
• Getinge AB;
• Biotronik SE & Co KG.

In 2025, the peripheral artery disease treatment devices market size is expected to reach approximately $7.6 billion. Analysts at Grand View Research believe that in the future, the CAGR will be 5.2%. Thus, by 2033, expenses may increase to $11.3 billion.^[1]

The volume of the global market for devices for sealing vessels for the year reached $2 billion

In 2024, expenditures on the global market for vessel sealing (ligation) devices reached $2 billion. The North American region accounted for almost 45% of global costs. Such data are provided in a Fortune Business Insights study, the results of which Zdrav.Expert reviewed in mid-July 2025.

Ligation tools are used during various surgeries to seal and dissect vessels and tissues, as well as lymphatic vessels of various diameters. One of the drivers of the industry, the authors of the report call the increase in the number of operations carried out, including those related to chronic diseases and injuries. According to an article published by the National Center for Biotechnology Information in 2020, about 310 million complex surgical procedures are carried out in the world every year. The situation is aggravated against the background of an aging population. Older people are more likely to show health problems, leading to increased demand for surgery. Accordingly, sales of various medical devices are growing, including devices for sealing vessels.

The development of minimally invasive surgery also has a positive impact on the market. Such procedures, compared to traditional open surgeries, provide numerous benefits, including reducing the risk of complications, speeding up patient recovery, reducing the rehabilitation period, and minimizing scarring. Minimally invasive operations are carried out in urological and gynecological diseases, in cardiac surgery, neurosurgery, in traumatology and orthopedics, etc. A growing number of patients preferring such interventions are encouraging medical organizations to focus on research and development aimed at creating cutting-edge tools for minimally invasive and robotic surgery, including ligation tools.

The study says that the pandemic had a negative impact on the industry. COVID-19 In the conditions of severe coronavirus restrictions and self-isolation of citizens, the transfer of planned surgical operations was observed. At the same time, production of products was disrupted, and massive disruptions occurred in supply chains. There are other deterrents. One of them, analysts call the relatively high cost of advanced devices for sealing vessels. Another problem for systems, health care especially in developing countries, is the low awareness of surgeons about these instruments.

By type of interventions, the market is segmented into general and laparoscopic surgery: the second direction provided the largest revenue in 2024. In terms of application, urology, gynecology, gastroenterology, cardiothoracic surgery, etc., are distinguished. The cardiothoracic sector brought the most revenue - 28.7% - due to the growing prevalence of cardiovascular diseases (CVD). Geographically, North America leads with 44.5% of spending, or $0.89 billion. Globally, the following are named major players:

• Medtronic;
• Johnson & Johnson Services;
• Olympus;
• B. Braun SE;
• Intuitive Surgical;
• Conmed;
• OmniGuide Holdings;
• Bowa-electronic GmbH & Co. KG.

Fortune Business Insights analysts believe that in the future, the CAGR in the market under consideration will be 6.5%. As a result, in 2025, the cost of devices for sealing vessels will reach $2.11 billion, and by 2032 it will rise to about $3.29 billion.^[2]

Production of the world's first robotic surgeons for vascular surgery with a needle puncture of the skin has begun

In early December 2024, the American company Microbot Medical introduced the compact robot surgeon Liberty for vessel operations. It is assumed that it can be used in neurovascular and cardiovascular operations, as well as in procedures on peripheral vessels. Read more here.

Main article: Surgery

The main and distinctive feature of endovascular surgery from other areas of medicine is that all interventions are performed without a scalpel, without large incisions, without general anesthesia. This makes it possible to perform interventions in those patients who are contraindicated by traditional surgical treatment.

The process of endovascular removal of blood clots (in the video below) is mesmerizing.

During the intervention, under local anesthesia, a low-traumatic 2-millimeter skin puncture in diameter in the area of ​ ​ the hand or groin is performed. Then, a thin instrument with a diameter of 2 mm is installed in the artery and then all surgical interventions are monitored using safe X-rays, all manipulations inside the vessel are displayed on the screen of special equipment - an angiograph.

{{# https://www.tadviser.ru/images/6/62/IMG 5512.MP4|100%|auto||Vacuum removal of blood clot from artery}}

After the intervention, there is no postoperative wound and sutures. Most diagnostic studies can be performed on an outpatient basis, saving time and finances. After surgery, patients can be discharged from the hospital after 1-3 days and return to their usual lifestyle.

Advantages of endovascular surgery over traditional:

1. Minimal trauma.

2. Minimal blood loss.

3. Absence of serious postoperative scars and scarring.

4. No anesthesia-related complications.

5. Rapid rehabilitation.

6. High efficiency of operations.

7. A better price.

Angiographs

• Angiographs